Carisbamate

Carisbamate (YKP509, formerly RWJ-333369) is a voltage-gated sodium channel modulator in Phase 3 as adjunctive therapy for drop seizures in Lennox-Gastaut syndrome (LGS), a severe pediatric-onset epileptic encephalopathy. This is a repositioned legacy compound, not a novel molecule. SK Life Science picked it up after Johnson & Johnson abandoned development around 2009 following an FDA non-approval letter in adjunctive partial-onset epilepsy and a string of failed efficacy readouts in migraine and neuropathic pain [1][3]. The Phase 3 trial NCT05219617 (n=252) is recruiting, with readout expected in the 2026 to 2027 window [4].

This is not a novel compound. Carisbamate has been in clinical development since the early 2000s under J&J as RWJ-333369. J&J ran Phase 3 programs in adjunctive partial-onset epilepsy and migraine prophylaxis, submitted an NDA for partial-onset epilepsy in 2008, received an FDA non-approval letter in 2009, and subsequently shelved the compound after additional failures in painful diabetic neuropathy and postherpetic neuralgia [3][5]. SK Life Science (the Korean conglomerate's pharma arm, which also markets cenobamate as Xcopri) re-acquired rights and repositioned the molecule for LGS, a rare refractory epilepsy where the regulatory bar is lower and any meaningful seizure reduction is clinically valued. No FDA breakthrough therapy, fast track, or accelerated approval designation has been publicly disclosed for the LGS program as of mid-2026. LGS itself qualifies for orphan drug designation in the US (prevalence under 200,000), but a formal designation for carisbamate could not be confirmed in FDA's public database. Because the Phase 3 trial enrolls patients aged 4 and older, the program is eligible for pediatric exclusivity (a 6-month patent/exclusivity extension under BPCA) if a Written Request is honored. The Phase 3 trial is the lone disclosed registrational study. Primary completion timing depends on enrollment pace, with readout most likely in late 2026 to mid 2027 [4]. SK has not provided guidance on a regulatory submission timeline.

Carisbamate modulates voltage-gated sodium channels, the molecular gates that let nerve cells fire electrical signals. In epilepsy, those channels misfire: neurons depolarize too easily and synchronize into the runaway electrical storms we call seizures. The standard antiepileptic playbook (phenytoin, carbamazepine, lacosamide, lamotrigine, oxcarbazepine) is built on partial sodium channel blockade, which raises the threshold for nerve firing without silencing the brain entirely. Carisbamate sits in that family with preclinical evidence that it preferentially suppresses the persistent (non-inactivating) sodium current, the slow leak component that drives sustained neuronal hyperexcitability rather than the fast spike. Preclinical work has also reported GABA-A receptor potentiation and effects on neuroinflammatory signaling in rodent models of epilepsy, both of which would, in theory, add to the seizure-suppression effect. None of these secondary pharmacologies have been confirmed in human studies [1][2]. As a class, sodium channel modulation is the most established mechanism in epilepsy, with multiple approved drugs on shelf going back to phenytoin in 1938. So the mechanistic foundation is solid. The harder question is whether carisbamate is meaningfully different from what is already approved, including SK's own cenobamate, which combines sodium channel blockade with GABA potentiation and has shown impressive seizure freedom rates in focal epilepsy. If carisbamate is just another competent sodium channel drug without confirmed secondary mechanisms in humans, the commercial case in a crowded LGS market is thin even with a positive trial.

NCT05219617 is a Phase 3 double-blind placebo-controlled adjunctive trial in LGS patients aged 4 and older with countable drop seizures, target enrollment 252 [4]. Primary endpoint is percentage change from baseline in 28-day frequency of drop seizures, which include tonic seizures (sudden whole-body muscle stiffening), atonic seizures (sudden loss of muscle tone causing collapse), and tonic-clonic seizures with potential to fall (stiffening followed by rhythmic jerking). That endpoint is the well-worn LGS key pathway: rufinamide, cannabidiol, and fenfluramine all earned LGS approvals on essentially the same construct. Comparator is placebo added to a stable background antiepileptic regimen. The design is conventional and FDA-friendly for LGS, which lowers regulatory uncertainty if the efficacy signal lands. Enrollment of 252 is in line with prior LGS key trials (cannabidiol's GWPCARE3/4 enrolled around 170 to 225). Pediatric inclusion matters because LGS onsets in childhood and most patients are diagnosed before age 8, and the pediatric arm potentially unlocks BPCA exclusivity if FDA issues a Written Request. Recruitment status is listed as recruiting as of mid-2026 [4]. The main design concern is not the structure but the comparator-adjusted effect size needed to differentiate from existing LGS therapies on the back end. A statistically significant but small effect would be approvable yet commercially soft.

Our model estimates a 16% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 51%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by the sponsor's thin or weak approval record, weak or limited earlier-phase results, a randomized design, and a comparator/control arm. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the dominant concern. Carisbamate's clinical history is a series of trials where the drug did something but not enough: J&J's key partial-onset epilepsy program produced statistically positive but commercially underwhelming effect sizes that, combined with FDA review concerns, ended in a 2009 non-approval letter, and the neuropathic pain program produced frankly negative diabetic neuropathy and postherpetic neuralgia (chronic nerve pain following shingles) trials [3][5]. LGS is a different setting with a more permissive endpoint, but the molecule's track record is not encouraging. Safety risk is moderate. Sodium channel modulators carry a class concern for serious cutaneous reactions including Stevens-Johnson syndrome (a rare, potentially life-threatening skin reaction with widespread blistering) and toxic epidermal necrolysis (a severe blistering skin condition involving large-scale skin detachment), and CNS adverse effects (somnolence, dizziness, gait disturbance). Prior carisbamate trials showed an acceptable but undifferentiated safety profile. IP and exclusivity risk is material and the most under-discussed concern. Carisbamate is a 20+ year old molecule, and the original composition-of-matter patents (filed in the late 1990s) have effectively expired or are near expiry. SK's commercial protection depends on method-of-use patents tied to LGS, formulation patents, NCE exclusivity (5 years if FDA agrees the active moiety has never been approved), orphan drug exclusivity (7 years for the LGS indication if granted), and pediatric exclusivity (6-month BPCA extension on top of any granted exclusivity). The Orange Book listing post-approval will determine how durable that wall is. If SK is relying primarily on regulatory exclusivities rather than enforceable patents, generic entry could compress the commercial window. Commercial risk is the sleeper. LGS therapy is crowded: clobazam (generic, first-line, cheap), rufinamide (Banzel, Eisai), cannabidiol (Epidiolex, Jazz Pharmaceuticals, ~$900M in 2023 sales across all indications), and fenfluramine (Fintepla, UCB after the Zogenix acquisition). Patients with LGS are typically on three to five concurrent antiepileptics. Payers resist adding a fifth at orphan drug pricing without a clear differentiation argument. Execution risk is modest: recruitment is ongoing and SK has run Phase 3 epilepsy trials before with cenobamate.

Worth watching for the readout, not for the science. The interesting data point is whether carisbamate delivers a placebo-adjusted drop-seizure reduction in the 25 to 30% range, which is roughly the band that rufinamide, cannabidiol, and fenfluramine occupied at their key trials. Anything north of 25% supports approval and competitive positioning. Anything south of 20% leaves SK with an approvable drug that has no commercial story against entrenched competitors. Market sizing: US LGS prevalence is roughly 30,000 to 50,000 patients (the syndrome accounts for 1 to 4% of childhood epilepsy and persists into adulthood). Orphan epilepsy drugs in LGS price in the $20,000 to $80,000 per year range (Fintepla and Epidiolex sit at the upper end). For a late-entrant adjunctive therapy facing entrenched competitors and likely formulary friction, a realistic peak revenue ceiling is sub-$200M annually in the US, with reasonable scenarios more often in the $50M to $150M band. That is a meaningful orphan asset but not a franchise-defining one. The company context matters more than the drug. SK Life Science's value driver is cenobamate (Xcopri), which has been growing US sales steadily since launch and is the asset their public-facing pipeline narrative is built around. Carisbamate is a portfolio diversification play, not a make-or-break program. A positive LGS readout adds a modest orphan revenue stream and validates SK's epilepsy franchise expansion. A negative readout is a write-down, not a company-changing event. Check back when NCT05219617 posts results, most likely late 2026 to mid 2027 [4]. Watch SK Life Science's pipeline disclosures, since the company is privately held under SK Group but reports key updates through parent disclosures and conference presentations.